Biodesix, Inc. BDSX 深 滬
等待開盤 06-15 09:30:00 美东时间
15.06
+0.260
+1.76%
華盛通- 最 高15.96
- 今 開15.01
- 成交量 2.11万股
- 最 低 14.81
- 昨 收 14.80
- 總市值 1.56亿
- 52周最高 20.21
- 市盈率 靜 --
- 換手率 0.20%
- 52周最低 5.00
- 委 比 -98.02%
- 總股本 1035.58万
- 歷史最高 639.80
- 量 比 0.44
- 振 幅 7.77%
- 歷史最低 3.436
- 每 手 1
- 風險率 3.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HC Wainwright & Co. Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $26
HC Wainwright & Co. analyst Yi Chen initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $26.
今天 18:17
Biodesix to Participate in Upcoming Investor Conferences
Biodesix, Inc. announced that its leadership team will participate in three upcoming investor conferences: the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, in Minneapolis; the William Blair 46th Annual Growth Stock Conference on June 3, 2026, in Chicago; and the TD Cowen Annual Tools/Dx Revolution on June 24, 2026, in Dana Point. The events will feature presentations and 1x1 meetings, with a live webcast available o...
05-21 10:00
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Biodesix Q1 2026 Earnings Call: Complete Transcript
Biodesix (NASDAQ:BDSX) released first-quarter financial results and hosted an e...
05-05 05:23
Biodesix shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 sales guidance with its midpoint above estimates.
Biodesix shares are trading higher after the company reported better-than-expec...
05-05 04:58
Biodesix Raises FY2026 Sales Guidance from $106.000M-$112.000M to $108.000M-$114.000M vs $108.680M Est
Biodesix (NASDAQ:BDSX) raises FY2026 sales outlook from $106.000 million-$112.000 million to $108.000 million-$114.000 million vs $108.680 million estimate.
05-05 04:02
Biodesix Announces First Quarter 2026 Results and Highlights
Biodesix reported Q1 2026 revenue of $25.6 million, a 42% year-over-year increase, with a 84% gross margin. The company raised its FY 2026 revenue guidance to $108-114 million, reflecting a 25% growth midpoint. Both diagnostic testing and development services saw strong growth, with test volumes up 29% and development revenue doubling. Biodesix also highlighted its recognition as a Top Workplace for the third consecutive year and plans to host a ...
05-04 20:01
Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
Biodesix, Inc. (Nasdaq: BDSX) will release its first quarter 2026 financial results on May 4 after market close. Management will host a conference call and webcast at 4:30 p.m. ET that day to discuss results and provide a business update. Listeners can register via the provided link. Analysts can join by dialing (800) 715-9871 (domestic) or +1 (646) 307-1963 (international) with passcode 2430172. Biodesix is a diagnostic solutions company offerin...
04-20 10:00
